Last reviewed · How we verify

monoclonal antibody 11D10 anti-idiotype

Alliance for Clinical Trials in Oncology · Phase 2 active Biologic

monoclonal antibody 11D10 anti-idiotype is a Biologic drug developed by Alliance for Clinical Trials in Oncology. It is currently in Phase 2 development. Also known as: TriAb.

At a glance

Generic namemonoclonal antibody 11D10 anti-idiotype
Also known asTriAb
SponsorAlliance for Clinical Trials in Oncology
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about monoclonal antibody 11D10 anti-idiotype

What is monoclonal antibody 11D10 anti-idiotype?

monoclonal antibody 11D10 anti-idiotype is a Biologic drug developed by Alliance for Clinical Trials in Oncology.

Who makes monoclonal antibody 11D10 anti-idiotype?

monoclonal antibody 11D10 anti-idiotype is developed by Alliance for Clinical Trials in Oncology (see full Alliance for Clinical Trials in Oncology pipeline at /company/alliance-for-clinical-trials-in-oncology).

Is monoclonal antibody 11D10 anti-idiotype also known as anything else?

monoclonal antibody 11D10 anti-idiotype is also known as TriAb.

What development phase is monoclonal antibody 11D10 anti-idiotype in?

monoclonal antibody 11D10 anti-idiotype is in Phase 2.

Related